Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - pemetrexed - concentrate for solution for infusion - 25 milligram(s)/millilitre - pemetrexed

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg - antineoplastic agents

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg - antineoplastic agents

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - pemetrexed disodium hemipentahydrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - pemetrexed disodium hemipentahydrate -

Canada - English - Health Canada

apotex inc - pemetrexed (pemetrexed disodium) - powder for solution - 500mg - pemetrexed (pemetrexed disodium) 500mg - antineoplastic agents

Canada - English - Health Canada

apotex inc - pemetrexed (pemetrexed disodium) - powder for solution - 100mg - pemetrexed (pemetrexed disodium) 100mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

ever valinject gmbh - pemetrexed - concentrate for solution for infusion - 25 milligram(s)/millilitre - pemetrexed

European Union - English - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. ciambra is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

United States - English - NLM (National Library of Medicine)

eugia us llc - pemetrexed disodium hemipentahydrate (unii: f4gsh45r4c) (pemetrexed - unii:04q9aiz7no) - pemetrexed for injection is indicated: • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (nsclc), with no egfr or alk genomic tumor aberrations. • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous nsclc. • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous nsclc whose disease has not progressed after four cycles of  platinum-based first-line chemotherapy. • as a single agent for the treatment of patients with recurrent, metastatic non-squamous, nsclc after prior chemotherapy. limitations of use : pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer [see clinical studies (14.1)] . pemetrexed for injection is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural